ERBB2 and non-small cell lung carcinoma: Furthermore, the TRAEMOS trial (NCT03784599) is investigating the clinical efficacy of such a combination regimen among advanced EGFR-mutant NSCLC patients with HER2 resistance who have progressed on EGFR-TKIs.